John Maraganore

Yaron Werber × John Maraganore × Sam Fazeli × Matt Gline

Lilly’s $3.8B atai Beckley acquisition, ahead of a pivotal readout, extends its prevention and DTC “tech company” strategy while hedging potential obesity pressure a decade out.Roivant’s imminent brepocitinib launch combines orphan-market economics with pricing expected closer to IVIG’s $225K than Vyvgart’s $870K, while Merck’s $3,800 enlicitide and tau ASO tolerability keep affordability and validation in focus.

Paul Matteis × John Maraganore × Eric Schmidt × Graig Suvannavejh

Biotech’s rally is being powered by real money, with the XBI outperforming the S&P 500 by 17% since September and fund flows positive for a second straight week, though Eric Schmidt cautions fundamentals may lag the tape.FDA delays, unclear CNPV criteria and potential pricing concessions remain execution risks, while a long-awaited 2026 IPO window, strategic M&A and upcoming Alector Phase 3 data could test whether clinical risk is being rewarded sustainably.

Paul Matteis × Sam Fazeli × John Maraganore × Graig Suvannaveijh

XBI rose 11.9% in a month versus 2% for the S&P as 22,000 payroll additions missed 75,000 consensus, reinforcing September rate-cut expectations.Sanofi fell 10% after positive amlitelimab Phase 3, highlighting Dupixent’s replacement challenge before its 2031 patent expiry.HARMONi-A and FLAURA2 lead the fall catalyst stack, while 90% screening failure clouds Lilly’s Alzheimer’s prevention commercial viability.

Grace Colón × John Maraganore × Paul Matteis × Eric Schmidt

MFN, not tariffs, is the sector’s key overhang; Paul Matteis says worst cases are “nowhere near priced into stocks.”Novo’s ex-Catalent Indianapolis facility has 43 Form 483 observations and two Regeneron CRLs, putting Scholar Rock’s September 22 SMA PDUFA at manufacturing risk.Vertex’s over-20% drop after a next-generation pain failure and slow suzetrigine launch makes strategy a key catalyst.

Sam Fazeli × John Maraganore × Nina Kjellson × Matt Gline

Monday's MFN order creates a 30-day voluntary period and 180 days of negotiations, with no government-scale implementation or US price pressure expected by end-2025.Because US pricing controllers generally prefer higher prices, MFN could raise ex-US prices and leave biotech underrepresented, while conditional $234B pledges, CMS's 2028 subQ test, and CytomX's $100M financing provide catalysts.

Daphne Zohar × Josh Schimmer × Tim Opler × John Maraganore × Paul Matteis

After April 7, XBI rose about 15% and BBC 30%, but remained down 12% and 24% year to date, offering no proof generalists returned.Makary’s FDA agenda could expand rare-disease optionality through smaller decisive datasets and conditional approvals, but staffing disruption and scientific independence remain execution risks.Cobenfy’s failed adjunctive study cut Citi’s peak-sales view to $2.8 billion, while real-world combination use and Alzheimer’s psychosis preserve upside scenarios.

Daphne Zohar × John Maraganore × Mike Yee × Sam Fazeli × John Crowley

Biotech entered JPM at “five out of 10,” with macro steering capital and Metsera’s obesity IPO testing a discriminating window.J&J’s $14.6 billion Intra-Cellular Therapies acquisition—following $1.22 billion raised and approximately 13× value creation—shows pharma’s appetite for derisked CNS assets, while China’s speed and cost make FDA trial reform a potential catalyst.